Novartis (SWX:NOVN) Stock Looks Reasonable Despite Its 89% Five Year Run

Novartis stock has delivered a strong 88.5% return over the past five years, and the valuation checks now point to a company that looks undervalued on market multiples but not as a straightforward bargain across every metric.

• Over the past 5 years, Novartis has returned 88.5%, which puts recent short term ups and downs into the context of a solid multi year share price performance.
• Protecting cash flows from key products such as Entresto, supported by the recent UK court win on its patent, can help underpin valuation, while ongoing legal proceedings and eventual patent expiry still leave earnings and cash flow exposed to future generic competition.
• The stock scores 4 out of 6 on the broader valuation checks, which is a mixed picture rather than a clear bargain or clear overvaluation, as shown in the valuation summary.

The issue now is whether Novartis shares still offer enough value support after this multi year run, or whether most of the easy upside has already been reflected in the price.

Find out why Novartis' 28.2% return over the last year is lagging behind its peers.

Is Novartis a Bargain on Earnings?

The P/E multiple suits Novartis because earnings remain a key driver of how investors value large pharmaceutical groups. Novartis trades on a P/E of 23.0x, which is slightly above the wider pharmaceuticals industry average of 21.7x but well below the peer group average of 44.3x. That already places the stock toward the lower half of its large cap peer range despite its established portfolio and global scale.

The fair P/E ratio implied by the model is 38.6x, which is materially higher than the current 23.0x. This suggests the market is applying a discount relative to what might be expected given Novartis' profitability profile, industry position and risk mix. Despite the recent support from the UK court win on Entresto, the current multiple still points to investors pricing the stock below that modelled fair range.

On the P/E multiple alone, Novartis stock appears undervalued compared with both its tailored fair ratio and many peers.

See what the numbers say about this price — find out in our valuation breakdown.

The Novartis Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Novartis give you a structured way to connect that P/E based valuation puzzle with explicit assumptions about what would need to happen to Novartis' growth, margins and earnings for the stock to be worth materially more or less than it is today. Each narrative links its number to a clear view of how growth, profitability and risks could develop. You can revisit these on the Community page as new information on Novartis' business emerges.

The community is split on Novartis, with one camp seeing balanced upside from new therapies and efficiency gains while another worries expectations already look stretched.

Bull case: roughly fairly valued

"Operational efficiency gains from portfolio streamlining (e.g., previous spin-offs and exiting non-core lines) and productivity improvements are driving core margin expansion and higher free cash flow..."

Read the full Bull Case to see why Novartis could be undervalued

Bear case: 29% overvalued

"Upcoming and ongoing generic erosion in major legacy products, notably Entresto, Tasigna, and Promacta, risks outpacing the ramp of newer launches if growth curves flatten..."

Read the full Bear Case to see why Novartis could be overvalued

Do you think there's more to the story for Novartis? Head over to our Community to see what others are saying!

The Bottom Line

For Novartis, the market multiples point to an undervalued stock relative to peers and to the tailored fair P/E range, although the wider valuation checks remain mixed rather than outright strong. That leaves the current discount looking more like a measured risk premium than a clear pricing error. The key question is whether Novartis can sustain earnings power from its core drugs while managing legal and patent pressures. The crux of the debate is whether that apparent discount compensates you for the risk that generic competition bites harder than expected over time.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com